Drugs · acquisition-cost intelligence
Gabapentin
· ingredient gabapentinGabapentinoids· GABAPENTIN 800 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.09799
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other gabapentin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| gabapentin | $0.03246 | −$0.06550 |
| gabapentin | $0.06824 | −$0.02970 |
| gabapentin | $0.08386 | −$0.01410 |
| gabapentin | $1.16 | +$1.07 |
| GABARONE | $8.52 | +$8.42 |
| Gralise | $10.20 | +$10.10 |
| Horizant | $17.92 | +$17.82 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 88% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.